BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28982149)

  • 1. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
    Gordiienko I; Shlapatska L; Kholodniuk V; Sklyarenko L; Gluzman DF; Clark EA; Sidorenko SP
    PLoS One; 2017; 12(10):e0185940. PubMed ID: 28982149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD150 and CD180 are involved in regulation of transcription factors expression in chronic lymphocytic leukemia cells.
    Gordiienko I; Shlapatska L; Kholodniuk VM; Kovalevska L; Ivanivskaya TS; Sidorenko SP
    Exp Oncol; 2017 Dec; 39(4):291-298. PubMed ID: 29284783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
    Shcherbina V; Gordiienko I; Shlapatska L; Ivanivska T; Sidorenko S
    Exp Oncol; 2020 Mar; 42(1):16-24. PubMed ID: 32231196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD150 and CD180 are negative regulators of IL-10 expression and secretion in chronic lymphocytic leukemia B cells.
    Shcherbina V; Gordiienko I; Shlapatska L; Gluzman D; Sidorenko S
    Neoplasma; 2021 Jul; 68(4):760-769. PubMed ID: 33904315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOLUBLE CD150 ISOFORM LEVEL IN PLASMA OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
    Gordiienko I; Shcherbina V; Shlapatska L
    Exp Oncol; 2024 Feb; 45(4):457-462. PubMed ID: 38328844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells.
    Porakishvili N; Memon A; Vispute K; Kulikova N; Clark EA; Rai KR; Nathwani A; Damle RN; Chiorazzi N; Lydyard PM
    Br J Haematol; 2011 May; 153(4):486-98. PubMed ID: 21443749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD150-mediated Akt signalling pathway in normal and malignant B cells.
    Yurchenko M; Shlapatska LM; Romanets OL; Ganshevskiy D; Kashuba E; Zamoshnikova A; Ushenin YV; Snopok BA; Sidorenko SP
    Exp Oncol; 2011 Mar; 33(1):9-18. PubMed ID: 21423089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of CD150-SH2D1A association in CD150 signaling in Hodgkin's lymphoma cell lines.
    Yurchenko MY; Kashuba EV; Shlapatska LM; Sivkovich SA; Sidorenko SP
    Exp Oncol; 2005 Mar; 27(1):24-30. PubMed ID: 15812353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD150 regulates JNK1/2 activation in normal and Hodgkin's lymphoma B cells.
    Yurchenko MY; Kovalevska LM; Shlapatska LM; Berdova GG; Clark EA; Sidorenko SP
    Immunol Cell Biol; 2010 Jul; 88(5):565-74. PubMed ID: 20231852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
    Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
    Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
    Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CD150 in tumors of the central nervous system: identification of a novel isoform.
    Romanets-Korbut O; Najakshin AM; Yurchenko M; Malysheva TA; Kovalevska L; Shlapatska LM; Zozulya YA; Taranin AV; Horvat B; Sidorenko SP
    PLoS One; 2015; 10(2):e0118302. PubMed ID: 25710480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of the expression of CD32 and CD180 receptors on CLL cells and MEC1 cell line.
    Tsertsvadze T; Mitskevich N; Ghirdaladze D; Porakishvili N
    Georgian Med News; 2015 Mar; (240):56-9. PubMed ID: 25879560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
    Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
    Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PHAGOCYTOSIS AND EXPRESSION OF FCg-RECEPTORS AND CD180 ON MONOCYTES IN CHRONIC LYMPHOCYTIC LEUKEMIA.
    Tsertsvadze T; Mitskevich N; Bilanishvili A; Girdaladze D; Porakishvili N
    Georgian Med News; 2017 Sep; (270):88-93. PubMed ID: 28972490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells.
    Mikhalap SV; Shlapatska LM; Yurchenko OV; Yurchenko MY; Berdova GG; Nichols KE; Clark EA; Sidorenko SP
    Blood; 2004 Dec; 104(13):4063-70. PubMed ID: 15315965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rewiring of sIgM-Mediated Intracellular Signaling through the CD180 Toll-like Receptor.
    Porakishvili N; Vispute K; Steele AJ; Rajakaruna N; Kulikova N; Tsertsvadze T; Nathwani A; Damle RN; Clark EA; Rai KR; Chiorazzi N; Lydyard PM
    Mol Med; 2015 Apr; 21(1):46-57. PubMed ID: 25611435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.
    Longo PG; Laurenti L; Gobessi S; Petlickovski A; Pelosi M; Chiusolo P; Sica S; Leone G; Efremov DG
    Leukemia; 2007 Jan; 21(1):110-20. PubMed ID: 17024114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia.
    Kawauchi K; Ogasawara T; Yasuyama M
    Int J Hematol; 2002 Jun; 75(5):508-13. PubMed ID: 12095152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1.
    Schrader A; Popal W; Lilienthal N; Crispatzu G; Mayer P; Jones D; Hallek M; Herling M
    Curr Cancer Drug Targets; 2014; 14(8):700-12. PubMed ID: 25348018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.